Market Overview

UPDATE: Stifel Nicolaus Raises PT to $6.51 on Boston Scientific Corporation S-ICD Checks

Related BSX
Boston Scientific's Symphion System Marks 1st US Surgery
Benzinga's Top Upgrades

Stifel Nicolaus reiterated Boston Scientific Corporation (NYSE: BSX) at Buy and increased the price target from $6.50 to $7.00.

Stifel Nicolaus noted, "Our recent physician checks with U.S. and EU electrophysiologists (EPs) reinforce our thesis that ultimately S-ICDs could represent 10% or more of overall ICD implants over time, if ongoing registry trials continue to suggest comparable performance versus traditional ICDs. We suspect this 10% penetration is greater than generally expected. These checks also reinforced our view that the S-ICD could potentially help re-invigorate BSX's beleaguered ICD franchise (~19% of 2012 estimated sales)."

Boston Scientific Corporation closed at $6.51 on Tuesday.

Latest Ratings for BSX

DateFirmActionFromTo
Oct 2014Goldman SachsUpgradesSellNeutral
Oct 2014BenchmarkUpgradesHoldBuy
Sep 2014NeedhamInitiates Coverage onHold

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BSX)

Around the Web, We're Loving...

Get Benzinga's Newsletters